{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:56:09Z","timestamp":1791140169212,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":4998,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.exphem.2008.04.013","type":"journal-article","created":{"date-parts":[[2008,6,18]],"date-time":"2008-06-18T04:43:59Z","timestamp":1213764239000},"page":"1278-1284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma\/leukemia cells derived from Jurkat line"],"prefix":"10.1016","volume":"36","author":[{"given":"Shuqing","family":"L\u00fc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhilong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2008.04.013_bib1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000468683","article-title":"Molecular structure of 20S and 26S proteasomes","volume":"47","author":"Tanahashi","year":"1993","journal-title":"Enzyme Protein"},{"key":"10.1016\/j.exphem.2008.04.013_bib2","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1146\/annurev.biochem.68.1.1015","article-title":"The 26S proteasome: a molecular machine designed for controlled proteolysis","volume":"68","author":"Voges","year":"1999","journal-title":"Ann Rev Biochem"},{"key":"10.1016\/j.exphem.2008.04.013_bib3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1097-2765(00)80341-X","article-title":"Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown","volume":"4","author":"Kisselev","year":"1999","journal-title":"Mol Cell"},{"key":"10.1016\/j.exphem.2008.04.013_bib4","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","article-title":"Proteasome inhibition as a novel therapeutic target in human cancer","volume":"23","author":"Rajkumar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.exphem.2008.04.013_bib5","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0092-8674(00)80171-3","article-title":"Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly","volume":"86","author":"Chen","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2008.04.013_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2174\/156800905774574075","article-title":"Anti-angiogenic and anti-tumor properties of proteasome inhibitors","volume":"5","author":"Daniel","year":"2005","journal-title":"Current Cancer Drug Targets"},{"key":"10.1016\/j.exphem.2008.04.013_bib7","doi-asserted-by":"crossref","first-page":"21648","DOI":"10.1074\/jbc.M001083200","article-title":"Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction","volume":"275","author":"Breitschopf","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2008.04.013_bib8","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1073\/pnas.070047997","article-title":"Bax degradation by the ubiquitin\/proteasome dependent pathway: involvement in tumor survival and progression","volume":"97","author":"Li","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2008.04.013_bib9","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1002\/j.1460-2075.1994.tb06878.x","article-title":"A proteasome inhibitor prevents activation of Nfkappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B","volume":"13","author":"Traenckner","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.exphem.2008.04.013_bib10","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/sj.cdd.4400436","article-title":"Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts","volume":"5","author":"An","year":"1998","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.exphem.2008.04.013_bib11","doi-asserted-by":"crossref","first-page":"13437","DOI":"10.1074\/jbc.272.20.13437","article-title":"Lactacystin and clasto- lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation","volume":"272","author":"Craiu","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2008.04.013_bib12","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/bjc.1998.183","article-title":"The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha- initiated apoptosis","volume":"77","author":"Delic","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.exphem.2008.04.013_bib13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/46.5.673","article-title":"Proteasome inhibition measurements: clinical application","volume":"46","author":"Lightcap","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.exphem.2008.04.013_bib14","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2008.04.013_bib15","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2008.04.013_bib16","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2008.04.013_bib17","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Assessment of proteasome inhibition for extending remissions (APEX) investigators. Bortezomib or high-dose dexamethazone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2008.04.013_bib18","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2008.04.013_bib19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/sj.onc.1208212","article-title":"Efficacy and mechanism of action of the proteasome HTLV-Iassociated adult T-cell leukemia\/lymphoma","volume":"24","author":"Nasr","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2008.04.013_bib20","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-03-0508","article-title":"Phase I study of bortezomib in refractory or relapsed acute leukemias","volume":"10","author":"Cortes","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2008.04.013_bib21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00280-005-0135-z","article-title":"Bortezomib interactions with chemotherapy agents in acute leukemia in vitro","volume":"58","author":"Horton","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.exphem.2008.04.013_bib22","series-title":"An International System for Human Cytogenetic Nomenclature","author":"ISCN","year":"2005"},{"key":"10.1016\/j.exphem.2008.04.013_bib23","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2008.04.013_bib24","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2174\/138161207780162908","article-title":"Proteasome as an emerging therapeutic target in cancer","volume":"13","author":"Zavrski","year":"2007","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.exphem.2008.04.013_bib25","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.leukres.2006.01.005","article-title":"Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr\/Abl","volume":"30","author":"Dasmahapatra","year":"2006","journal-title":"Leuk Res."},{"key":"10.1016\/j.exphem.2008.04.013_bib26","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.013_bib27","doi-asserted-by":"crossref","first-page":"31440","DOI":"10.1016\/S0021-9258(19)84056-5","article-title":"Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa","volume":"281","author":"Fribley","year":"2006","journal-title":"J Biol Chem."},{"key":"10.1016\/j.exphem.2008.04.013_bib28","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-kappa B as a therapeutic target in multiple myeloma","volume":"277","author":"Hideshima","year":"2002","journal-title":"J Biol Chem."},{"key":"10.1016\/j.exphem.2008.04.013_bib29","first-page":"1","article-title":"Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors","volume":"8","author":"Cheriyath","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.exphem.2008.04.013_bib30","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1182\/blood-2004-02-0547","article-title":"Targeting mitochondria to overcome conventional and bortezomib\/ proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells","volume":"104","author":"Chauhan","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2008.04.013_bib31","first-page":"6174","article-title":"Blockade of Hsp27 overcomes Bortezomib\/proteasome inhibitor PS-341 resistance in lymphoma cells","volume":"63","author":"Chauhan","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2008.04.013_bib32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2141.2006.06132.x","article-title":"Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib","volume":"134","author":"Shringarpure","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2008.04.013_bib33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/sj.leu.2404414","article-title":"Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells","volume":"21","author":"Kraus","year":"2007","journal-title":"Leukemia"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X08001847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X08001847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:25:50Z","timestamp":1759566350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X08001847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0301472X08001847"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2008.04.013","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma\/leukemia cells derived from Jurkat line","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2008.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}